skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Fluvastatin mitigates SARS-CoV-2 infection in human lung cells

iScience, 2021-12, Vol.24 (12), p.103469-103469, Article 103469 [Peer Reviewed Journal]

2021 The Author(s) ;2021 The Author(s). ;2021 The Author(s) 2021 ;ISSN: 2589-0042 ;EISSN: 2589-0042 ;DOI: 10.1016/j.isci.2021.103469 ;PMID: 34812415

Full text available

Citations Cited by
  • Title:
    Fluvastatin mitigates SARS-CoV-2 infection in human lung cells
  • Author: Zapatero-Belinchón, Francisco J. ; Moeller, Rebecca ; Lasswitz, Lisa ; van Ham, Marco ; Becker, Miriam ; Brogden, Graham ; Rosendal, Ebba ; Bi, Wenjie ; Carriquí-Madroñal, Belén ; Islam, Koushikul ; Lenman, Annasara ; Gunesch, Antonia P. ; Kirui, Jared ; Pietschmann, Thomas ; Överby, Anna K. ; Jänsch, Lothar ; Gerold, Gisa
  • Subjects: Drugs ; Virology
  • Is Part Of: iScience, 2021-12, Vol.24 (12), p.103469-103469, Article 103469
  • Description: Clinical data of patients suffering from COVID-19 indicates that statin therapy, used to treat hypercholesterolemia, is associated with a better disease outcome. Whether statins directly affect virus replication or influence the clinical outcome through modulation of immune responses is unknown. We therefore investigated the effect of statins on SARS-CoV-2 infection in human lung cells and found that only fluvastatin inhibited low and high pathogenic coronaviruses in vitro and ex vivo in a dose-dependent manner. Quantitative proteomics revealed that fluvastatin and other tested statins modulated the cholesterol synthesis pathway without altering innate antiviral immune responses in infected lung epithelial cells. However, fluvastatin treatment specifically downregulated proteins that modulate protein translation and viral replication. Collectively, these results support the notion that statin therapy poses no additional risk to individuals exposed to SARS-CoV-2 and that fluvastatin has a moderate beneficial effect on SARS-CoV-2 infection of human lung cells. [Display omitted] •Fluvastatin inhibits low (HCoV-229E) and high (SARS-CoV-2) pathogenic coronaviruses•SARS-CoV-2 infection does not affect statin-induced cholesterol biosynthesis arrest•Statin treatment does not alter SARS-CoV-2 innate immune responses in vitro•Fluvastatin downregulates protein translation and viral replication pathways Drugs; Virology
  • Publisher: United States: Elsevier Inc
  • Language: English
  • Identifier: ISSN: 2589-0042
    EISSN: 2589-0042
    DOI: 10.1016/j.isci.2021.103469
    PMID: 34812415
  • Source: PubMed Central
    SWEPUB Freely available online
    DOAJ Directory of Open Access Journals
Back to results list
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait